Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343926 | 1.00 | MGLL (0.44) | MGLLCA12CA1CA2CA9 | |
| SCHEMBL3343921 | 1.00 | MGLL (0.44) | MGLLCA12CA1CA2CA9 | |
| SCHEMBL13409451 | 0.89 | MGLL (0.42) | MGLLCA12CA1CA2CA9 | |
| SCHEMBL3346315 | 0.88 | MEN1 (0.53) | MGLLCA12CA1CA2CA9 | |
| SCHEMBL3346306 | 0.88 | MEN1 (0.53) | MGLLCA12CA1CA2CA9 | |
| SCHEMBL3346312 | 0.88 | MEN1 (0.53) | MGLLCA12CA1CA2CA9 | |
| SCHEMBL3343995 | 0.86 | CA12 (0.50) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL3343985 | 0.86 | CA12 (0.50) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL3343992 | 0.86 | CA12 (0.50) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL10064863 | 0.84 | MIF (0.41) | MGLLCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858776-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2010-12-28 | — | — | US | disclosed |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1996202-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7294622-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| EP-1845089-A1 | Novel lactams and uses thereof | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007104933-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| US-20060089346-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089346-A1 | Novel lactams and uses thereof | BACE1, BACE2, APH1B | MGLL 1902/4885CA12 3947/4885CA1 1360/4885 |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | APP, BACE1, PSEN1 | MGLL 3202/4885CA12 4256/4885CA1 792/4885 |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | BACE1, BACE2, APP | MGLL 1664/4885CA12 3865/4885CA1 1157/4885 |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | NOTCH1, HES1, NOTCH2 | MGLL 3835/4885CA12 1249/4885CA1 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.